Corvus Pharmaceuticals Inc

1
NAS:CRVS (USA)  
$ 4.89 +0.345 (+7.58%) 12:15 PM EST
At Loss
P/B:
22.75
Market Cap:
$ 292.37M
Enterprise V:
$ 279.99M
Volume:
450.14K
Avg Vol (2M):
1.32M
Trade In:
Volume:
450.14K
At Loss
Avg Vol (2M):
1.32M

Business Description

Description
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Name Current Vs Industry Vs History
Cash-To-Debt 117.66
Equity-to-Asset 0.21
Debt-to-Equity 0.03
Debt-to-EBITDA -0.01
Interest Coverage No Debt
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 17.91
9-Day RSI 21.29
14-Day RSI 25.95
6-1 Month Momentum % 402.81
12-1 Month Momentum % 426.47

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.92
Quick Ratio 0.92
Cash Ratio 0.9

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -20
Shareholder Yield % 0.4
Name Current Vs Industry Vs History
ROE % -157.89
ROA % -108.89
ROIC % -88.11
ROC (Joel Greenblatt) % -2334.33
ROCE % -69.58

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 22.75
Price-to-Tangible-Book 22.75
EV-to-EBIT -11.16
EV-to-EBITDA -11.2
EV-to-FCF -12.65
Earnings Yield (Greenblatt) % -8.96
FCF Yield % -7.57

Financials (Next Earnings Date:2025-03-19 Est.)

CRVS's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:CRVS

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Corvus Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -0.92
Beta 1.24
Volatility % 106.79
14-Day RSI 25.95
14-Day ATR ($) 0.791412
20-Day SMA ($) 7.5245
12-1 Month Momentum % 426.47
52-Week Range ($) 1.3 - 10
Shares Outstanding (Mil) 64.26

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Corvus Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Corvus Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Corvus Pharmaceuticals Inc Frequently Asked Questions

What is Corvus Pharmaceuticals Inc(CRVS)'s stock price today?
The current price of CRVS is $4.89. The 52 week high of CRVS is $10.00 and 52 week low is $1.30.
When is next earnings date of Corvus Pharmaceuticals Inc(CRVS)?
The next earnings date of Corvus Pharmaceuticals Inc(CRVS) is 2025-03-19 Est..
Does Corvus Pharmaceuticals Inc(CRVS) pay dividends? If so, how much?
Corvus Pharmaceuticals Inc(CRVS) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1